Jefferies Comments on Stryker 1Q Knee Results

Stryker's SYK 1Q knee results across the board were down from 4Q, Jefferies reports. “The worldwide market was flat and U.S. was down 4%; sequentially, U.S. was 500bp slower,” Jefferies writes. “It is a bit confounding that knees decelerated so precipitously in 1Q given that several companies have been selling the add-on devices and it speaks to the very low penetration thus far. “While pricing wasn't disclosed, other custom cutting blocks are priced in the range of $1,000-$1,500—making even modest penetration meaningful; although there have also been reports of heavily discounting. A conservative assumption of 10% penetration into Stryker's U.S. knee business with an ASP of $1,000 would yield a modest $10-15mn in incremental annual revenue. However, the incremental revenue may not be as important as the competitive share gains possible now that Triathlon has a custom option.” Jefferies closed Tuesday at $62.74.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsHealth CareHealth Care EquipmentJefferiesstryker
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!